Complete remission of primary cutaneous intravascular large B-cell lymphoma with R-CHOP followed by rituximab monotherapy

Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12499. Epub 2017 May 16.

Authors

Ioanna Pantelaki¹, Christian Tigges¹, Tabea Nußbaum¹, Frank Oellig², Ulrike Wieland³, Alexander Kreuter¹

Affiliations

¹ Department of Dermatology, Venereology, and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, University Witten-Herdecke, , Oberhausen, Germany.
² Institute of Pathology, Mülheim an der Ruhr, Mülheim, Germany.
³ National Reference Center for Papilloma- and Polyomaviruses, Institute of Virology, Uniklinik Köln, University of Cologne, Köln, Germany.

PMID: 28508527
DOI: 10.1111/dth.12499

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / pathology
Middle Aged
Prednisone / therapeutic use
Remission Induction
Rituximab / administration & dosage
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Treatment Outcome
Vincristine / therapeutic use

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone